Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.

ABSTRACT:

Context

Focal adhesion kinase (FAK) and Src are overexpressed and activated in many cancers and have been associated with tumor progression. The role of the Src-FAK complex has not been characterized in papillary and anaplastic thyroid cancer (PTC and ATC).

Objective

The goal of this study was to determine the role of Src and FAK in the growth and invasion of PTC and ATC.

Design

PTC and ATC cells were treated with the oral Src inhibitor, AZD0530, to determine the consequences of Src inhibition using growth and invasion assays. FAK and phospho-FAK levels were analyzed in cell lines as well as in PTC tumor samples.

Results

AZD0530 treatment inhibited the growth and invasion in four of five thyroid cancer cell lines, and inhibition did not correlate with basal lev

SUBMITTER: Schweppe RE 

PROVIDER: S-EPMC2690419 | biostudies-literature | 2009 Jun

REPOSITORIES: biostudies-literature